Onward Therapeutics Closes NT$900 Million (approximately US$28 Million) Series B Financing to Advance Clinical-Stage Oncology Pipeline
First capital increase since relocating global headquarters to Taiwan; Company targets Emerging Stock Board registration by the end of 2027 TAIPEI and EPALINGES, Switzerland and PARIS, Nov. 17, 2026 /PRNewswire/ -- Onward Therapeutics, Inc. ("Onward Therapeutics" or the "Company") today...
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


